Jump to content

Tirzepatide

From Wikipedia

Tirzepatide[1] be an antidiabetic medication dem use to treat type 2 diabetes[2][3][4] den for weight loss.[5][6] Dem dey administer tirzepatide via subcutaneous injections (under de skin).[2] Insyd de United States, dem dey sell under de brand name Mounjaro for diabetes treatment den Zepbound for weight loss den treatment of obstructive sleep apnea.[7]

Tirzepatide be a gastric inhibitory polypeptide (GIP) analog den a GLP-1 receptor agonist. De most common side effects dey include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, den abdominal pain.[2][8]

Eli Lilly and Company develop am, na dem approve tirzepatide for treatment of diabetes insyd de U.S. insyd May 2022,[2] insyd de European Union insyd September 2022, insyd Canada insyd November 2022,[9] den insyd Australia insyd December 2022. De U.S. Food and Drug Administration (FDA) dey consider am a first-in-class medication.[10][11] Na de FDA approve am for weight loss insyd November 2023.[12] Also insyd November 2023, de U.K. Medicines and Healthcare products Regulatory Agency revise de indication for tirzepatide (as Mounjaro) to include de treatment for weight management den weight loss.[13] Insyd December 2024, na de FDA revise de indication for tirzepatide (as Zepbound) to include de treatment of moderate to severe obstructive sleep apnea. Insyd 2023, na tirzepatide be de 110th-most commonly prescribed medication insyd de U.S., plus more dan six million prescriptions.[14][15]

References

[edit | edit source]
  1. ↑ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
  2. 1 2 3 4 "FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes". U.S. Food and Drug Administration (FDA) (Press release). 13 May 2022. Archived from the original on 13 May 2022. Retrieved 13 May 2022.
  3. ↑ Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA (January 2021). "Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes". The Journal of Clinical Endocrinology and Metabolism. 106 (2): 388–396. doi:10.1210/clinem/dgaa863. PMC 7823251. PMID 33236115.
  4. ↑ Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A (December 2018). "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept". Molecular Metabolism. 18: 3–14. doi:10.1016/j.molmet.2018.09.009. PMC 6308032. PMID 30473097.
  5. ↑ "DailyMed - ZEPBOUND- tirzepatide injection, solution". dailymed.nlm.nih.gov (in English). Archived from the original on 2023-11-20. Retrieved 2025-12-09.
  6. ↑ "FDA Approves New Medication for Chronic Weight Management". U.S. Food and Drug Administration (FDA) (Press release). 8 November 2023. Archived from the original on 8 November 2023. Retrieved 9 November 2023.
  7. ↑ "FDA Approves First Medication for Obstructive Sleep Apnea". U.S. Food and Drug Administration (FDA) (Press release). 20 December 2024. Archived from the original on 20 December 2024. Retrieved 21 December 2024.
  8. ↑ Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G (November 2022). "Tirzepatide: A Systematic Update". Int J Mol Sci. 23 (23) 14631. doi:10.3390/ijms232314631. PMC 9741068. PMID 36498958.
  9. ↑ "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023. Retrieved 5 January 2023.
  10. ↑ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023.
  11. ↑ "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023. Retrieved 5 January 2023.
  12. ↑ Kolata G (8 November 2023). "F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovy". The New York Times. Archived from the original on 9 November 2023. Retrieved 9 November 2023.
  13. ↑ "MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss". GOV.UK (Press release). 8 November 2023. Archived from the original on 16 November 2023. Retrieved 17 November 2023.
  14. ↑ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
  15. ↑ "Drug and Health Product Submissions Under Review (SUR): New drug submissions completed". Health Canada. 10 March 2021. Archived from the original on 5 January 2023. Retrieved 5 January 2023.
[edit | edit source]
Dem retrieve am from "https://gpe.wikipedia.org/w/index.php?title=Tirzepatide&oldid=82492"